Literature DB >> 32112560

Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.

Lili Zhang1,2, Magid Awadalla1,2, Syed S Mahmood3, Anju Nohria4, Malek Z O Hassan1, Franck Thuny5,6,7, Daniel A Zlotoff2, Sean P Murphy1, James R Stone8, Doll Lauren Alexandra Golden1, Raza M Alvi1, Adam Rokicki1,2, Maeve Jones-O'Connor1, Justine V Cohen9, Lucie M Heinzerling10, Connor Mulligan1, Merna Armanious11, Ana Barac12, Brian J Forrestal12, Ryan J Sullivan9, Raymond Y Kwong13, Eric H Yang14, Rongras Damrongwatanasuk11, Carol L Chen15, Dipti Gupta15, Michael C Kirchberger10, Javid J Moslehi16, Otavio R Coelho-Filho17, Sarju Ganatra18, Muhammad A Rizvi19, Gagan Sahni20, Carlo G Tocchetti21, Valentina Mercurio21, Michael Mahmoudi22, Donald P Lawrence9, Kerry L Reynolds9, Jonathan W Weinsaft3,15, A John Baksi23,24, Stephane Ederhy25, John D Groarke4, Alexander R Lyon26,27, Michael G Fradley11, Paaladinesh Thavendiranathan28, Tomas G Neilan1,2.   

Abstract

AIMS: Myocarditis is a potentially fatal complication of immune checkpoint inhibitors (ICI). Sparse data exist on the use of cardiovascular magnetic resonance (CMR) in ICI-associated myocarditis. In this study, the CMR characteristics and the association between CMR features and cardiovascular events among patients with ICI-associated myocarditis are presented. METHODS AND
RESULTS: From an international registry of patients with ICI-associated myocarditis, clinical, CMR, and histopathological findings were collected. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block. In 103 patients diagnosed with ICI-associated myocarditis who had a CMR, the mean left ventricular ejection fraction (LVEF) was 50%, and 61% of patients had an LVEF ≥50%. Late gadolinium enhancement (LGE) was present in 48% overall, 55% of the reduced EF, and 43% of the preserved EF cohort. Elevated T2-weighted short tau inversion recovery (STIR) was present in 28% overall, 30% of the reduced EF, and 26% of the preserved EF cohort. The presence of LGE increased from 21.6%, when CMR was performed within 4 days of admission to 72.0% when CMR was performed on Day 4 of admission or later. Fifty-six patients had cardiac pathology. Late gadolinium enhancement was present in 35% of patients with pathological fibrosis and elevated T2-weighted STIR signal was present in 26% with a lymphocytic infiltration. Forty-one patients (40%) had MACE over a follow-up time of 5 months. The presence of LGE, LGE pattern, or elevated T2-weighted STIR were not associated with MACE.
CONCLUSION: These data suggest caution in reliance on LGE or a qualitative T2-STIR-only approach for the exclusion of ICI-associated myocarditis. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiovascular magnetic resonance; Immune checkpoint inhibitor; Myocarditis

Mesh:

Substances:

Year:  2020        PMID: 32112560      PMCID: PMC7205467          DOI: 10.1093/eurheartj/ehaa051

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   35.855


  45 in total

1.  2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology.

Authors:  Ornella Leone; John P Veinot; Annalisa Angelini; Ulrik T Baandrup; Cristina Basso; Gerald Berry; Patrick Bruneval; Margaret Burke; Jagdish Butany; Fiorella Calabrese; Giulia d'Amati; William D Edwards; John T Fallon; Michael C Fishbein; Patrick J Gallagher; Marc K Halushka; Bruce McManus; Angela Pucci; E René Rodriguez; Jeffrey E Saffitz; Mary N Sheppard; Charles Steenbergen; James R Stone; Carmela Tan; Gaetano Thiene; Allard C van der Wal; Gayle L Winters
Journal:  Cardiovasc Pathol       Date:  2011-12-03       Impact factor: 2.185

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Detection and Monitoring of Acute Myocarditis Applying Quantitative Cardiovascular Magnetic Resonance.

Authors:  Florian von Knobelsdorff-Brenkenhoff; Johannes Schüler; Serkan Dogangüzel; Matthias A Dieringer; Andre Rudolph; Andreas Greiser; Peter Kellman; Jeanette Schulz-Menger
Journal:  Circ Cardiovasc Imaging       Date:  2017-02       Impact factor: 7.792

4.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

Authors:  Douglas B Johnson; Justin M Balko; Margaret L Compton; Spyridon Chalkias; Joshua Gorham; Yaomin Xu; Mellissa Hicks; Igor Puzanov; Matthew R Alexander; Tyler L Bloomer; Jason R Becker; David A Slosky; Elizabeth J Phillips; Mark A Pilkinton; Laura Craig-Owens; Nina Kola; Gregory Plautz; Daniel S Reshef; Jonathan S Deutsch; Raquel P Deering; Benjamin A Olenchock; Andrew H Lichtman; Dan M Roden; Christine E Seidman; Igor J Koralnik; Jonathan G Seidman; Robert D Hoffman; Janis M Taube; Luis A Diaz; Robert A Anders; Jeffrey A Sosman; Javid J Moslehi
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

5.  Cardiovascular magnetic resonance in myocarditis: A JACC White Paper.

Authors:  Matthias G Friedrich; Udo Sechtem; Jeanette Schulz-Menger; Godtfred Holmvang; Pauline Alakija; Leslie T Cooper; James A White; Hassan Abdel-Aty; Matthias Gutberlet; Sanjay Prasad; Anthony Aletras; Jean-Pierre Laissy; Ian Paterson; Neil G Filipchuk; Andreas Kumar; Matthias Pauschinger; Peter Liu
Journal:  J Am Coll Cardiol       Date:  2009-04-28       Impact factor: 24.094

6.  PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Authors:  Paul T Nghiem; Shailender Bhatia; Evan J Lipson; Ragini R Kudchadkar; Natalie J Miller; Lakshmanan Annamalai; Sneha Berry; Elliot K Chartash; Adil Daud; Steven P Fling; Philip A Friedlander; Harriet M Kluger; Holbrook E Kohrt; Lisa Lundgren; Kim Margolin; Alan Mitchell; Thomas Olencki; Drew M Pardoll; Sunil A Reddy; Erica M Shantha; William H Sharfman; Elad Sharon; Lynn R Shemanski; Michi M Shinohara; Joel C Sunshine; Janis M Taube; John A Thompson; Steven M Townson; Jennifer H Yearley; Suzanne L Topalian; Martin A Cheever
Journal:  N Engl J Med       Date:  2016-04-19       Impact factor: 91.245

7.  Coronary vasospasm as the underlying cause for chest pain in patients with PVB19 myocarditis.

Authors:  A Yilmaz; H Mahrholdt; A Athanasiadis; H Vogelsberg; G Meinhardt; M Voehringer; E-M Kispert; C Deluigi; H Baccouche; E Spodarev; K Klingel; R Kandolf; U Sechtem
Journal:  Heart       Date:  2008-01-29       Impact factor: 5.994

8.  Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis.

Authors:  Christoph Gräni; Christian Eichhorn; Loïc Bière; Venkatesh L Murthy; Vikram Agarwal; Kyoichi Kaneko; Sarah Cuddy; Ayaz Aghayev; Michael Steigner; Ron Blankstein; Michael Jerosch-Herold; Raymond Y Kwong
Journal:  J Am Coll Cardiol       Date:  2017-10-17       Impact factor: 24.094

9.  Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.

Authors:  Tomas G Neilan; Mace L Rothenberg; Laleh Amiri-Kordestani; Ryan J Sullivan; Richard M Steingart; William Gregory; Subramanian Hariharan; Tarek A Hammad; JoAnn Lindenfeld; Martin J Murphy; Javid J Moslehi
Journal:  Oncologist       Date:  2018-05-25

10.  T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging.

Authors:  Vanessa M Ferreira; Stefan K Piechnik; Erica Dall'Armellina; Theodoros D Karamitsos; Jane M Francis; Ntobeko Ntusi; Cameron Holloway; Robin P Choudhury; Attila Kardos; Matthew D Robson; Matthias G Friedrich; Stefan Neubauer
Journal:  JACC Cardiovasc Imaging       Date:  2013-09-04
View more
  68 in total

Review 1.  Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients.

Authors:  Srilakshmi Vallabhaneni; Kathleen W Zhang; Jose A Alvarez-Cardona; Joshua D Mitchell; Henning Steen; Pamela K Woodard; Daniel J Lenihan
Journal:  Int J Cardiovasc Imaging       Date:  2021-05-12       Impact factor: 2.357

Review 2.  Cardiotoxicity of Systemic Melanoma Treatments.

Authors:  Neha Mukunda; Srilakshmi Vallabhaneni; Benedicte Lefebvre; Michael G Fradley
Journal:  Curr Treat Options Oncol       Date:  2022-02-22

Review 3.  Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.

Authors:  Daniel Lenihan; Joseph Carver; Charles Porter; Jennifer E Liu; Susan Dent; Paaladinesh Thavendiranathan; Joshua D Mitchell; Anju Nohria; Michael G Fradley; Iskra Pusic; Keith Stockerl-Goldstein; Anne Blaes; Alexander R Lyon; Sarju Ganatra; Teresa López-Fernández; Rupal O'Quinn; Giorgio Minotti; Sebastian Szmit; Daniela Cardinale; Jose Alvarez-Cardona; Giuseppe Curigliano; Tomas G Neilan; Joerg Herrmann
Journal:  CA Cancer J Clin       Date:  2020-09-10       Impact factor: 508.702

Review 4.  The cancer patient and cardiology.

Authors:  José Luis Zamorano; Christer Gottfridsson; Riccardo Asteggiano; Dan Atar; Lina Badimon; Jeroen J Bax; Daniela Cardinale; Antonella Cardone; Elizabeth A M Feijen; Péter Ferdinandy; Teresa López-Fernández; Chris P Gale; John H Maduro; Javid Moslehi; Torbjørn Omland; Juan Carlos Plana Gomez; Jessica Scott; Thomas M Suter; Giorgio Minotti
Journal:  Eur J Heart Fail       Date:  2020-10-02       Impact factor: 15.534

5.  Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis.

Authors:  Paaladinesh Thavendiranathan; Lili Zhang; Amna Zafar; Zsofia D Drobni; Syed S Mahmood; Marcella Cabral; Magid Awadalla; Anju Nohria; Daniel A Zlotoff; Franck Thuny; Lucie M Heinzerling; Ana Barac; Ryan J Sullivan; Carol L Chen; Dipti Gupta; Michael C Kirchberger; Sarah E Hartmann; Jonathan W Weinsaft; Hannah K Gilman; Muhammad A Rizvi; Bojan Kovacina; Caroline Michel; Gagan Sahni; Ana González-Mansilla; Antonio Calles; Francisco Fernández-Avilés; Michael Mahmoudi; Kerry L Reynolds; Sarju Ganatra; Juan José Gavira; Nahikari Salterain González; Manuel García de Yébenes Castro; Raymond Y Kwong; Michael Jerosch-Herold; Otavio R Coelho-Filho; Jonathan Afilalo; Eduardo Zataraín-Nicolás; A John Baksi; Bernd J Wintersperger; Oscar Calvillo-Arguelles; Stephane Ederhy; Eric H Yang; Alexander R Lyon; Michael G Fradley; Tomas G Neilan
Journal:  J Am Coll Cardiol       Date:  2021-03-30       Impact factor: 24.094

Review 6.  What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.

Authors:  Marina Frayberg; Anthony Yung; Leyre Zubiri; Daniel A Zlotoff; Kerry L Reynolds
Journal:  Curr Treat Options Oncol       Date:  2021-05-26

Review 7.  Role of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis.

Authors:  Stéphane Ederhy; Joe-Elie Salem; Laurent Dercle; Abrar Saqif Hasan; Marion Chauvet-Droit; Pascal Nhan; Samy Ammari; Bruno Pinna; Alban Redheuil; Samia Boussouar; Stephane Champiat; Laurie Soulat-Dufour; Ariel Cohen
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

Review 8.  The Role of Cardiovascular MRI in Cardio-Oncology.

Authors:  Wendy Bottinor; Cory R Trankle; W Gregory Hundley
Journal:  Heart Fail Clin       Date:  2020-10-28       Impact factor: 3.179

Review 9.  Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Alan H Baik; Katy K Tsai; David Y Oh; Mandar A Aras
Journal:  Clin Sci (Lond)       Date:  2021-03-12       Impact factor: 6.124

10.  Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque.

Authors:  Udo Hoffmann; Tomas G Neilan; Zsofia D Drobni; Raza M Alvi; Jana Taron; Amna Zafar; Sean P Murphy; Paula K Rambarat; Rayma C Mosarla; Charlotte Lee; Daniel A Zlotoff; Vineet K Raghu; Sarah E Hartmann; Hannah K Gilman; Jingyi Gong; Leyre Zubiri; Ryan J Sullivan; Kerry L Reynolds; Thomas Mayrhofer; Lili Zhang
Journal:  Circulation       Date:  2020-10-02       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.